Iwona Gorczyca-Glowacka

Kielce, SK, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Etiology of heart failure across the ejection fraction spectrum and association with mortality - insight from the HEart failuRe ObsErvational study (HEROES).

Etiology of heart failure across the ejection fraction spectrum and association with mortality - insight from the HEart failuRe ObsErvational study (HEROES).

Journal: Advances in medical sciences

Published: February 23, 2026

Health-related quality of life and mortality in patients with atrial fibrillation and the whole spectrum of heart failure: Insights from the Heart Failure Observational Study (HEROES).

Health-related quality of life and mortality in patients with atrial fibrillation and the whole spectrum of heart failure: Insights from the Heart Failure Observational Study (HEROES).

Journal: Kardiologia polska

Published: February 18, 2026

How does direct oral anticoagulant dosage affect long-term prognosis in patients with atrial fibrillation and heart failure? Results from the HEart failure ObsErvational Study (HEROES).

How does direct oral anticoagulant dosage affect long-term prognosis in patients with atrial fibrillation and heart failure? Results from the HEart failure ObsErvational Study (HEROES).

Journal: Kardiologia polska

Published: May 19, 2025

Atrial fibrillation in patients with heart failure with reduced, mildly reduced, and preserved ejection fraction: A report from the HEart failuRe ObsErvational Study (HEROES).

Atrial fibrillation in patients with heart failure with reduced, mildly reduced, and preserved ejection fraction: A report from the HEart failuRe ObsErvational Study (HEROES).

Journal: Kardiologia polska

Published: March 28, 2025

Real-life implementation of guidelines for heart failure management.

Real-life implementation of guidelines for heart failure management.

Journal: Kardiologia polska

Published: June 25, 2023

Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society.

Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society.

Journal: Kardiologia polska

Published: January 22, 2023

Rules for the use of reduced doses of non-vitamin K antagonist oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation. The opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society

Rules for the use of reduced doses of non-vitamin K antagonist oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation. The opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society

Journal: Kardiologia polska

Published: November 14, 2022

Is transesophageal echocardiography necessary before electrical cardioversion in patients treated with non-vitamin K antagonist oral anticoagulants? Current evidence and practical approach.

Is transesophageal echocardiography necessary before electrical cardioversion in patients treated with non-vitamin K antagonist oral anticoagulants? Current evidence and practical approach.

Journal: Cardiology journal

Published: May 06, 2021

Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease.

Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease.

Journal: Cardiology journal

Published: January 01, 2020

Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.

Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.

Journal: Cardiology journal

Published: February 24, 2019

Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.

Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.

Journal: Kardiologia polska

Published: November 14, 2017

Evaluation of the recommended prevention of thrombosis in hospitalised patients with atrial fibrillation and high thromboembolism risk.

Evaluation of the recommended prevention of thrombosis in hospitalised patients with atrial fibrillation and high thromboembolism risk.

Journal: Kardiologia polska

Published: August 23, 2017

Showing 1-12 of 21

Last Updated: 09/26/2026